Section Arrow
QTTB.NASDAQ
- Q32 Bio
Quotes are at least 15-min delayed:2026/06/01 16:17 EDT
After Hours
Last
 11.66
0 (0.00%)
Bid
11.55
Ask
11.66
High 11.66 
Low 11.39 
Volume 166 
Regular Hours (Closed)
Last
 11.66
+0.61 (+5.52%)
Day High 
12.5 
Prev. Close
11.05 
1-M High
13.15 
Volume 
1.07M 
Bid
11.55
Ask
11.66
Day Low
10.785 
Open
10.82 
1-M Low
4.97 
Market Cap 
187.37M 
Currency 美元 
P/E 4.19 
%Yield -- 
10-SMA 7.64 
20-SMA 6.55 
50-SMA 6.31 
52-W High 13.15 
52-W Low 1.345 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
2.78/-2.03
Enterprise Value
195.78M
Balance Sheet
Book Value Per Share
2.73
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
53.74M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
AIMAIM ImmunoTech Inc.0.8986+0.4908+120.35%-- 
After Hours 0.8383 -0.0603 -6.71%
GNTAGenenta Science SpA1.65+0.62+60.19%-- 
After Hours 1.63 -0.02 -1.21%
OTLKOutlook Therapeutics0.84635+0.11635+15.94%-- 
After Hours 0.84 -- --
RXRXRecursion Pharmaceuticals3.79+0.2+5.57%-- 
After Hours 3.7501 -- --
ADTXAditxt Inc.0.113-0.0042-3.58%-- 
After Hours 0.1268 +0.0138 +12.21%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.